A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Description

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

Conditions

Acute Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Primary Unilateral Bunionectomy

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Condition
Acute Pain
Intervention / Treatment

-

Contacts and Locations

Sheffield

ALLEVIATE 2 Site 001108, Sheffield, Alabama, United States, 35660

Little Rock

ALLEVIATE 2 Site 001106, Little Rock, Arkansas, United States, 72211

Tampa

ALLEVIATE 2 Site 001103, Tampa, Florida, United States, 33613

Atlanta

ALLEVIATE 2 Site 001102, Atlanta, Georgia, United States, 30331

Overland Park

ALLEVIATE 2 Site 001107, Overland Park, Kansas, United States, 66212

Pasadena

ALLEVIATE 2 Site 001105, Pasadena, Maryland, United States, 21122

Houston

Alleviate 2 001113, Houston, Texas, United States, 77043

McAllen

ALLEVIATE 2 Site 001104, McAllen, Texas, United States, 78501

San Antonio

ALLEVIATE 2 Site 001111, San Antonio, Texas, United States, 78240

Salt Lake City

ALLEVIATE 2 Site 001101, Salt Lake City, Utah, United States, 84107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Surgical, postsurgical, or anesthetic complication that could confound the interpretation of efficacy, safety, or tolerability data in the study.
  • * Deviation from the surgical, postsurgical, or anesthetic protocol that could confound the interpretation of efficacy, safety, or tolerability data in the study.
  • * Evidence of hemodynamic instability or respiratory insufficiency.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Tris Pharma, Inc.,

Todd M Bertoch, MD, PRINCIPAL_INVESTIGATOR, CenExel JBR

Study Record Dates

2025-03